Report of the first international workshop on onchocerciasis-associated epilepsy by Colebunders, R et al.
EDITORIAL Open Access
Report of the first international workshop
on onchocerciasis-associated epilepsy
Robert Colebunders1* , Michel Mandro2, Alfred K. Njamnshi3, Michel Boussinesq4, An Hotterbeekx1,
Joseph Kamgno5, Sarah O’Neill6, Adrian Hopkins7, Patrick Suykerbuyk1, Maria-Gloria Basáñez8, Rory J. Post9,
Belén Pedrique10, Pierre-Marie Preux11, Wilma A. Stolk12, Thomas B. Nutman13 and Richard Idro14
Abstract
Background: Recently, several epidemiological studies performed in Onchocerca volvulus-endemic regions have
suggested that onchocerciasis-associated epilepsy (OAE) may constitute an important but neglected public health
problem in many countries where onchocerciasis is still endemic.
Main text: On October 12–14th 2017, the first international workshop on onchocerciasis-associated epilepsy (OAE)
was held in Antwerp, Belgium. The workshop was attended by 79 participants from 20 different countries. Recent
research findings strongly suggest that O. volvulus is an important contributor to epilepsy, particularly in meso- and
hyperendemic areas for onchocerciasis. Infection with O. volvulus is associated with a spectrum of epileptic seizures,
mainly generalised tonic-clonic seizures but also atonic neck seizures (nodding), and stunted growth. OAE is
characterised by an onset of seizures between the ages of 3–18 years. Multidisciplinary working groups discussed
topics such as how to 1) strengthen the evidence for an association between onchocerciasis and epilepsy, 2)
determine the burden of disease caused by OAE, 3) prevent OAE, 4) improve the treatment/care for persons with
OAE and affected families, 5) identify the pathophysiological mechanism of OAE, and 6) deal with misconceptions,
stigma, discrimination and gender violence associated with OAE.
An OAE Alliance was created to increase awareness about OAE and its public health importance, stimulate research
and disseminate research findings, and create partnerships between OAE researchers, communities, advocacy groups,
ministries of health, non-governmental organisations, the pharmaceutical industry and funding organizations.
Conclusions: Although the exact pathophysiological mechanism underlying OAE remains unknown, there is
increasing evidence that by controlling and eliminating onchocerciasis, OAE will also disappear. Therefore, OAE
constitutes an additional argument for strengthening onchocerciasis elimination efforts. Given the high numbers
of people with epilepsy in O. volvulus-endemic regions, more advocacy is urgently needed to provide anti-epileptic
treatment to improve the quality of life of these individuals and their families.
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Multilingual Abstracts
Please see Additional file 1 for translations of the ab-
stract into the five official working languages of the
United Nations.
Background
The filarial nematode Onchocerca volvulus is known to
cause skin and ocular disease, including blindness, in
addition to an excess risk of mortality that increases with
microfilarial load [1, 2]. Proposed causes of this excess
mortality may be multifarious, including parasite-
specific and more generalised immunosuppression [3, 4],
in addition to neuro-hormonal involvement, including
epilepsy [5]. However, because microfilariae (mf) have
never been shown to enter the central nervous system
(CNS), onchocerciasis has not been considered to dir-
ectly cause epilepsy or other brain disorders. However,
as early as 1938, Casis Sacre described a syndrome char-
acterized by epileptic seizures, stunted growth and
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mental retardation in patients with onchocerciasis in
Chiapas and Oaxaca States, in Mexico [6]. Since then, a
number of studies in Africa have also suggested an asso-
ciation between O. volvulus infection and epilepsy [7–
10]. In a study in an O. volvulus-endemic area in the
Mbam Valley in Cameroon, Boussinesq et al. showed
that the highest prevalence of epilepsy was observed in
villages very close to the Mbam River and in villages
with a high community microfilarial load [11]. In the late
1990s, a nodding syndrome epidemic was reported in
South Sudan [7] and northern Uganda [12]. Case-
control studies revealed an association between nodding
syndrome and O. volvulus infection [12, 13], but O. vol-
vulus infection per se was still not considered to under-
lie the cause of this syndrome. Moreover, nodding
syndrome was thought to occur only in Uganda, South
Sudan and Tanzania; nodding syndrome was felt to have
a different aetiology than the one driving the epilepsy
observed in other onchocerciasis-endemic regions. In
2012, a conference on nodding syndrome was organised
by the World Health Organization (WHO) and the
Ugandan Ministry of Health in Kampala. During this
conference, a case definition for nodding syndrome was
proposed, but the problem of the high prevalence of
other forms of epilepsy in onchocerciasis-endemic re-
gions was not addressed. In 2015, a follow-up confer-
ence organised in Gulu, Uganda, also only focused on
nodding syndrome. Recently, several epidemiological
studies performed in O. volvulus-endemic regions sug-
gested that nodding syndrome should probably be con-
sidered as a subset of onchocerciasis-associated epilepsy
(OAE) [14] and that OAE may constitute an important
but neglected public health problem in many countries
where onchocerciasis is still endemic [15]. Therefore, a
steering committee was established to organise an inter-
national workshop on OAE.
Main text
First International Workshop on Onchocerciasis-
Associated Epilepsy
From 12–14 October 2017, the first international work-
shop on onchocerciasis-associated epilepsy (OAE) was
held in Antwerp, Belgium (https://www.uantwerpen.be/
en/conferences/oae-2017/).
This workshop aimed to: 1) update the knowledge
about the different clinical presentations of epilepsy ob-
served in onchocerciasis-endemic regions, 2) create
awareness about the public health importance of OAE,
and 3) create an OAE Alliance by bringing together or-
ganizations and researchers involved in onchocerciasis
elimination efforts and those involved in the treatment
of and research on epilepsy.
The workshop was attended by 79 participants from
20 different countries, among them 28 African nationals.
Participants included a wide variety of experts, among
them: neurologists, paediatricians, infectious disease ex-
perts, ophthalmologists, epidemiologists, mathematical
modellers, parasitologists, onchocerciasis experts, immu-
nologists, pathologists, pharmacologists, anthropologists,
public health experts, primary health care specialists and
medical entomologists. The workshop was also attended
by representatives of the Africa Commission of the
International League against Epilepsy, the International
Bureau of Epilepsy, and a limited number of representa-
tives of affected communities and of African Ministries
of Health. However, despite a broad invitation list (in-
cluding non-governmental organisations [NGOs] and
pharmaceutical companies), only one NGO (Light for
the World) attended; none of the pharmaceutical com-
panies producing anti-epileptic treatment were present
at the workshop.
The workshop included oral and poster presentations of
new research findings and discussions of topics in working
groups. The abstract book of the workshop can be found
at https://www.uantwerpen.be/en/research-groups/oae/.
Topics discussed during the workshop
Multi-disciplinary working groups discussed the follow-
ing topics:
 How to strengthen the body of evidence supporting
the association between infection with O. volvulus
and epilepsy
 What is the burden of disease caused by OAE
 How to prevent OAE
 How to organise surveillance for OAE
 How to improve the treatment/care for persons with
OAE and affected families
 How to deal with misconceptions, stigma,
discrimination and gender violence associated with
OAE
 How to identify the pathophysiological mechanism
of OAE
 What should be the components of an OAE
prevention and treatment/care policy plan
 How to implement and fund such an OAE policy
plan
Main conclusions of the working groups are presented
at the end of this paper. Moreover, several papers result-
ing from the working group discussions will be included
in the thematic series on OAE.
Main research findings presented at the workshop
1. There is a high prevalence and incidence of epilepsy
in many O. volvulus-endemic regions where
onchocerciasis is insufficiently controlled. In recently
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performed door to door studies in O. volvulus meso-
and hyperendemic villages close to onchocerciasis
vector (blackflies: Diptera, Simuliidae) breeding sites,
in the Democratic Republic of the Congo (DRC)
[16], Cameroon [17, 18], Tanzania [19], Uganda [20]
and South Sudan [21], the prevalence of epilepsy
was found to be between 2 and 8%. This rate is
much higher than the median epilepsy prevalence in
O. volvulus non-endemic regions in Africa, which is
estimated to be 1.4% [22].
2. In a retrospective cohort study in the Mbam Valley,
Cameroon, 5–10-year old children examined in
1991–1993 were grouped into cohorts based on
their microfilarial density (0, 1–25, 26–129, > 130
mf/2 skin snips). The cumulative incidence of
epilepsy was shown to increase with increasing
microfilarial density during childhood [23].
3. For a given microfilarial load, the relative risk of
onchocerciasis-associated mortality is statistically
significantly higher in younger people (those aged
less than 20 years) than in the older age groups
(aged 20 years and above) [2]. This cannot be
explained by the skin or ocular complications of
onchocerciasis but may be explained by OAE-related
mortality, given that the peak age of onset of
epilepsy in O. volvulus-endemic regions is between 3
and 18 years [15] and that children with epilepsy in
onchocerciasis-endemic regions experience high
mortality rates [24].
4. In O. volvulus hyperendemic areas, epilepsy presents
within a spectrum of different types of seizures. The
most frequent type of seizures is a generalised tonic-
clonic seizure. Other forms include: atonic neck
seizures (nodding), myoclonic neck seizures, and
absence seizures. A minority of individuals have
concomitant severe stunting with no delay or
delayed external signs of sexual development
(the so-called Nakalanga syndrome) [25]. OAE is
characterised by an onset of seizures between the
age of 3–18 years [15].
5. In several O. volvulus-endemic areas with a high
prevalence of epilepsy, the annual mass drug
administration (MDA) of ivermectin was found
not to have been very successful in decreasing
epidemiological indicators of O. volvulus infection,
primarily because of low therapeutic coverages [15,
26]. Modelling studies also confirm that annual
MDA may not be sufficient to break O. volvulus
transmission in areas with very high transmission
intensity [26]. Therefore, additional onchocerciasis
elimination strategies, including increasing the
frequency of treatment (e.g. to 6-monthy) and
larviciding of vector breeding sites in fast-flowing rivers,
may need to be considered in highly endemic areas.
6. Strengthening ivermectin MDA by increasing
coverage and compliance, giving the drug twice a
year, and implementation of blackfly control, seem
to be the best ways to rapidly decrease the incidence
of OAE. In northern Uganda, the incidence of
nodding syndrome and other forms of epilepsy
started to decrease with the introduction of
ivermectin MDA; nodding syndrome cases ceased
appearing when a combination of the twice a year
distribution of ivermectin together with the
deployment of larviciding in the river basins known
to contain simuliid breeding sites was implemented
[15]. The effect of ivermectin in preventing the onset
of OAE is also suggested by recent case-control
studies in the DRC showing that persons with
epilepsy were less likely to have taken ivermectin
compared to age-, sex- and village-matched controls
[16, 27], and by an age-shift to older age groups of
persons with epilepsy in onchocerciasis-endemic
regions where MDA had been implemented for a
long time [17, 18].
7. A randomised clinical trial is ongoing in the Logo
health zone in the Ituri Province in DRC to evaluate
whether ivermectin can decrease the frequency of
seizures in persons with OAE [28]. A similar trial
in Uganda is investigating whether doxycycline
(a tetracycline antibiotic with rigorously quantified
macrofilaricidal efficacy via eliminating the worm’s
endosymbiotic Wolbachia [29]) is able to decrease
the frequency of seizures in persons with nodding
syndrome [30]. Among patients enrolled in this trial,
both asymptomatic and symptomatic Plasmodium
falciparum malaria infections were associated with
poor seizure control [31].
8. The pathophysiological mechanism of OAE is still
unknown but might well be a consequence of O.
volvulus-triggered cross-reactive auto-antibodies.
Recently, neurotoxic anti-leiomodin-1 antibodies
were detected in patients with nodding syndrome,
antibodies that cross-react with O. volvulus
tropomyosin/troponin [32].
9. Epilepsy-related stigma is wide spread in all O.
volvulus-endemic regions. Lack of evidence-based
awareness campaigns about epilepsy (and its
association with O. volvulus) means that
misconceptions and stigma persevere and are not
dealt with. Misconceptions about the origin of the
condition influences health-seeking behaviour.
Families who have a child with epilepsy, may hide
the child at home due to fear of stigmatisation and
social exclusion, and turn to traditional healers for
treatment, which exacerbates the treatment gap.
Women bear a disproportionate burden both as
caretakers and patients [33]. Although the research
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is insufficient, it is well-known to clinicians and
social workers that girls with epilepsy are often
victims of violence and sexual abuse. The sexual
abuse of boys affected by epilepsy is also under-
researched. Given the important psycho-social and
economic consequences of OAE, the burden of
disease caused by OAE appears to be considerable,
but the exact magnitude still needs to be determined.
10.There is an urgent need to improve the treatment
gap for anti-epileptic treatment and ivermectin
coverage to improve patients’ psycho-social and
economic well-being. If patients’ seizures are
controlled by anti-epileptic drugs, the psychosocial
issues and economic prospects of their lives will
improve considerably. Workshop attendees, therefore,
agreed to establish an OAE policy plan and to test the
feasibility and cost effectiveness of this plan in pilot
projects.
Conclusions
Evidence is mounting that infection with O. volvulus
is associated with a spectrum of epileptic seizures and
stunting. However, this body of evidence needs to be
strengthened by carefully conducted epidemiological
studies.
Given the high prevalence of epilepsy in meso- and
hyper-endemic onchocerciasis areas, the burden of dis-
ease caused by onchocerciasis needs to be re-estimated
taking into account the burden of disease caused by
OAE.
Although the exact pathophysiological mechanism of
OAE remains unknown, there is increasing epidemio-
logical evidence that by eliminating O. volvulus infection,
these forms of epilepsy will disappear.
OAE constitutes an additional argument for strength-
ening onchocerciasis elimination efforts.
Given the high numbers of people with epilepsy in O.
volvulus-endemic regions, more advocacy is urgently
needed to provide anti-epileptic treatment in order to
improve the quality of life of those affected and their
families.
A community based treatment and care programme
for epilepsy needs to be established in remote oncho-
cerciasis endemic regions with a high prevalence of
epilepsy. Such a programme should include a surveil-
lance system for epilepsy to allow early diagnosis and
treatment and a health education and training
programme to decrease misconceptions and stigma re-
lated to epilepsy.
Long-term sustainable treatment/care plans for indi-
viduals with OAE need to be developed because those
affected will continue to suffer even after onchocerciasis
has been eliminated.
An OAE Alliance was created to increase awareness
about OAE and its public health importance, stimulate re-
search, disseminate research findings and create partner-
ships between OAE researchers, communities, advocacy
groups, ministries of health, NGOs, the pharmaceutical
industry and funding organizations.
A follow-up workshop is planned in 2018–19 in
Uganda
Additional file
Additional file 1: Multilingual abstracts in the five official working
languages of the United Nations. (PDF 947 kb)
Abbreviations
CNS: Central nervous system; DRC: Democratic Republic of the Congo;
MDA: Mass drug administration; NGO: Non-governmental organisation;
OAE: Onchocerciasis-associated epilepsy; WHO: World Health Organization
Acknowledgements
We thank Jo Van Dael, Silvie Van Den Branden and Dimitri Geelhand de
Merxem for their invaluable help in organising the 1st International
Workshop on OAE. Our gratitude also goes to all workshop participants for
their enthusiastic engagement in all the activities and break-out sessions of
the workshop.
Funding
The workshop received funding from VLIR UOS, the European Research
Council (grant ERCPoC 768815), and Janssen pharmaceuticals.
Availability of data and Materials
Data sharing is not applicable as no datasets were generated or analysed in
this paper.
Authors’ contributions
RC conceived the workshop together with AH and PS. RC prepared the first
draft. All others contributed to the writing of the paper for intellectual input.
All authors read and approved the final version.
Competing interest
The authors declare that they have no competing interests.
Ethics approval and consent to participate
All research projects mentioned in the manuscript received approval from
the respective national ethics review committees and informed consent was
obtained from all study participants.
Consent for publication
Not applicable.
Author details
1Global Health Institute, University of Antwerp, Antwerp, Belgium. 2Provincial
Health Division of Ituri, Bunia, Democratic Republic of the Congo.
3Department of Neurology, Yaoundé Central Hospital/University of Yaoundé
1, Brain Research Africa Initiative (BRAIN), Yaoundé, Cameroon. 4Institut de
Recherche pour le Développement (IRD), Montpellier, France. 5Centre for
Research on Filariasis and other Tropical Diseases (CRFilMT), and Faculty of
Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé,
Cameroon. 6Department of Public Health, Institute of Tropical Medicine,
Antwerp, Belgium. 7Neglected and Disabling Diseases of Poverty Consultant,
Kent, UK. 8London Centre for Neglected Tropical Disease Research, Imperial
College London, London, UK. 9London School of Hygiene & Tropical
Medicine and Liverpool John Moores University, London, UK. 10Drugs for
Neglected Diseases initiative, Geneva, Switzerland. 11Preux Pierre-Marie,
INSERM, University Limoges, CHU Limoges, UMR_S 1094, Tropical
Neuroepidemiology, Institute of Neuroepidemiology and Tropical Neurology,
CNRS FR 3503 GEIST, 87000 Limoges, France. 12Department of Public Health,
Colebunders et al. Infectious Diseases of Poverty  (2018) 7:23 Page 4 of 5
Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The
Netherlands. 13Laboratory of Parasitic Diseases, National Institutes of Health,
Bethesda, Maryland, USA. 14Makerere University, College of Health Sciences,
Kampala, Uganda.
Received: 29 December 2017 Accepted: 6 March 2018
References
1. Little MP, Breitling LP, Basáñez MG, Alley ES, Boatin BA. Association between
microfilarial load and excess mortality in onchocerciasis: an epidemiological
study. Lancet. 2004;363(9420):1514–21.
2. Walker M, Little MP, Wagner KS, Soumbey-Alley EW, Boatin BA, Basáñez MG.
Density-dependent mortality of the human host in onchocerciasis:
relationships between microfilarial load and excess mortality. PLoS Negl
Trop Dis. 2012;6(3):e1578.
3. Satoguina J, Mempel M, Larbi J, Badusche M, Löliger C, Adjei O, et al.
Antigenspecific T regulatory-1 cells are associated with immunosuppression
in a chronic helminth infection (onchocerciasis). Microbes Infect. 2002;4:
1291–300.
4. Cooper PJ, Espinel I, Paredes W, Guderian RH, Nutman TB. (1998) Impaired
tetanus-specific cellular and humoral responses following tetanus
vaccination in human onchocerciasis: a possible role for interleukin-10. J
Infect Dis. 1998;178(4):1133–8.
5. Ovuga E, Kipp W, Mungherera M, Kasoro S. Epilepsy and retarded growth in
a hyperendemic focus of onchocerciasis in rural western Uganda. East Afr
Med J. 1992;69(10):554–6.
6. Casis SG. El sindrome epiléptico y sus relaciones con la oncocercosis. Bol
Salubr Hig (Mex). 1938;1:11–31.
7. Kipp W, Kasoro S, Burnham G. Onchocerciasis and epilepsy in Uganda.
Lancet. 1994;343(8890):183–4.
8. Kaiser C, Kipp W, Asaba G, Mugisa C, Kabagambe G, Rating D, et al. The
prevalence of epilepsy follows the distribution of onchocerciasis in a west
Ugandan focus. Bull World Health Organ. 1996;74(4):361–7.
9. Pion SDS, Kaiser C, Boutros-Toni F, Cournil A, Taylor MM, Meredith SE, et al.
Epilepsy in onchocerciasis endemic areas: systematic review and meta-
analysis of population-based surveys. PLoS Negl Trop Dis. 2009;3(6):e461.
10. Boussinesq M, Pion SDS, Ngangue D, Kamgno J. Relationship between
onchocerciasis and epilepsy: a matched case-control study in the Mbam
Valley, Republic of Cameroon. Trans R Soc Trop Med Hyg. 2002;96(5):537–41.
11. Tumwine JK, Vandemaele K, Chungong S, Richer M, Anker M. Ayana Y, et al
Clinical and epidemiologic characteristics of nodding syndrome in Mundri
County, southern Sudan. Afr Health Sci. 2012;12(3):242–8.
12. Dowell SF, Sejvar JJ, Riek L, Vandemaele KA, Lamunu M, Kuesel AC, et al.
Nodding syndrome. Emerg Infect Dis. 2013;19(9):1374–84.
13. Foltz JL, Makumbi I, Sejvar JJ, Malimbo M, Ndyomugyenyi R, Atai-Omoruto
AD, et al. An epidemiologic investigation of potential risk factors for
nodding syndrome in Kitgum District. Uganda. PLoS One. 2013;8(6):e66419.
14. Wamala JF, Malimbo M, Tepage F, Lukwago L, Okot CL, Cannon RO, et al.
Nodding syndrome may be only the ears of the hippo. PLoS Negl Trop Dis.
2015;9(8):e0003880.
15. Colebunders R, Njamnshi AK, van Oijen M, Mukendi D, Kashama JM, Mandro
M, et al. Onchocerciasis-associated epilepsy: from recent epidemiological
and clinical findings to policy implications. Epilepsia Open. 2017;2:144–52.
16. Levick B, Laudisoit A, Tepage F, Ensoy-Musoro C, Mandro M, Bonareri Osoro
C, et al. High prevalence of epilepsy in onchocerciasis endemic regions in
the Democratic Republic of the Congo. PLoS Negl Trop Dis. 2017;11(7):
e0005732.
17. Njamnshi AK, Zoung-Kanyi Bissek AC, Tabah EN, Ngarka L,Chokote E, Nfor
LN, et al. Age shift of persons with epilepsy in Bilomo, Cameroon, following
ivermectin mass drug administration for onchocerciasis. In: 1st International
Workshop on Onchocerciasis-Associated Epilepsy. 12-14 October 2017,
Antwerp, Belgium. [Abstract 17]. Available: https://www.uantwerpen.be/
images/uantwerpen/container42952/files/20171023%20Programma%
20boekje%20FINAL.pdf (Accessed 21 Dec 2017).
18. Boullé C, Njamnshi AK, Dema F, Mengnjo M, Siewe J, Tatah GY et al.
Epilepsy prevalence and cohort age shift: evidence for the benefit of
ivermectin mass drug administration on onchocerciasis-associated epilepsy
in the Mbam Valley, Cameroon. In: 1st International Workshop on
Onchocerciasis-Associated Epilepsy, 12-14 October 2017, Antwerp, Belgium
Abstract 16. 2017 [Abstract 16]. Available: https://www.uantwerpen.be/
images/uantwerpen/container42952/files/20171023%20Programma%
20boekje%20FINAL.pdf (Accessed 21 Dec 2017).
19. Mmbando BP, Mnacho M, Makunde M, Kakorozya A, Matuja W, Greter H,
et al. High prevalence of epilepsy and onchocerciasis after 20 years of
ivermectin use in four villages of the Mahenge area in Tanzania In: 10th
European Conference on Tropical Medicine and International Health, 16-20
October 2017, Antwerp, Belgium. [Abstract 3OS5.4]. Available: http://www.
ectmih2017.be/site/assets/files/1014/abstracts_organised_sessions-1.pdf
(Accessed 21 Dec 2017).
20. Mbonye MK, Opar BT, Gumisiriza N, Lawko T, Makumbi I, Idro R et al.
Prevalence and annual incidence of nodding syndrome and other forms of
epilepsy in onchocerciasis endemic areas in northern Uganda. In: 1st
International Workshop on Onchocerciasis-Associated Epilepsy 12-14
October 2017, Antwerp, Belgium. [Abstract 24]. Available: https://www.
uantwerpen.be/images/uantwerpen/container42952/files/20171023%
20Programma%20boekje%20FINAL.pdf (Accessed 21 Dec 2017).
21. Colebunders R, Hendy A, Mokili JL, Wamala JF, Kaducu J, Kur L, et al.
Nodding syndrome and epilepsy in onchocerciasis endemic regions:
comparing preliminary observations from South Sudan and the Democratic
Republic of the Congo with data from Uganda. BMC Res Notes. 2016;9:182.
22. Ba-Diop A, Marin B, Druet-Cabanac M, Ngoungou EB, Newton CR, Preux PM.
Epidemiology, causes, and treatment of epilepsy in sub-Saharan Africa.
Lancet Neurol. 2014;13(10):1029–44.
23. Chesnais CB, Njamnshi AK, Zoung-Kanyi Bissek AC, Tatah GY, Nana-Djeunga
HC, Kamgno J et al. First evidence by a cohort study in Cameroon that
onchocerciasis does induce epilepsy In: 1st International Workshop on
Onchocerciasis-Associated Epilepsy. 12-14 October 2017, Antwerp, Belgium.
[Abstract 15]. Available: https://www.uantwerpen.be/images/uantwerpen/
container42952/files/20171023%20Programma%20boekje%20FINAL.pdf
(Accessed 21 Dec 2017).
24. Kaiser C, Asaba G, Kasoro S, Rubaale T, Kabagambe G, Mbabazi M. Mortality
from epilepsy in an onchocerciasis-endemic area in West Uganda. Trans R
Soc Trop Med Hyg. 2007;101(1):48–55.
25. Kipp W, Burnham G, Bamuhiiga J, Leichsenring M. The Nakalanga syndrome
in Kabarole District, Western Uganda. Am J Trop Med Hyg. 1996;54(1):80–3.
26. Stolk WA, Walker M, Coffeng LE, Basáñez MG, de Vlas SJ. Required duration
of mass ivermectin treatment for onchocerciasis elimination in Africa: a
comparative modelling analysis. Parasit Vectors. 2015;8:552.
27. Colebunders R, Mandro M, Mokili JL, Mucinya G, Mambandu G, Pfarr K, et al.
Risk factors for epilepsy in Bas-Uele Province, Democratic Republic of the
Congo: a case-control study. Int J Infect Dis. 2016;49:1–8.
28. Colebunders R, Mandro M, Mukendi D, Dolo H, Suykerbuyk P, Van Oijen M.
Ivermectin treatment in patients with onchocerciasis-associated epilepsy:
protocol of a randomized clinical trial. JMIR Res Protoc. 2017;6(8):e137.
29. Walker M, Specht S, Churcher TS, Hoerauf A, Taylor MJ, Basáñez MG.
Therapeutic efficacy and macrofilaricidal activity of doxycycline for the
treatment of river blindness. Clin Infect Dis. 2015;60(8):1199–207.
30. Idro R, Opar B, Wamala J, Abbo C, Onzivua S, Mwaka DA, et al. Is nodding
syndrome an Onchocerca volvulus-induced neuroinflammatory disorder?
Uganda's story of research in understanding the disease. Int J Infect Dis.
2016;45:112–7.
31. Ogwang R, Odongkara SP, Torach R, Marsh K, Idro R. Assymptomatic
Plasmodium falciparum malaria and seizure control in childre and
adolescents with nodding syndrome. In: 1st International Workshop on
Onchocerciasis-Associated Epilepsy, 12-14 October, Antwerp, Belgium.
[Abstract 10]. Available: https://www.uantwerpen.be/images/uantwerpen/
container42952/files/20171023%20Programma%20boekje%20FINAL.pdf.
Accessed 21 Dec 2017.
32. Johnson TP, Tyagi R, Lee PR, Lee MH, Johnson KR, Kowalak J, Elkahloun A,
Medynets M, Hategan A, Kubofcik J, Sejvar J, Ratto J, Bunga S, Makumbi I,
Aceng JR, Nutman TB, Dowell SF, Nath A. Nodding syndrome may be an
autoimmune reaction to the parasitic worm Onchocerca volvulus. Sci Transl
Med. 2017;9(377). https://doi.org/10.1126/scitranslmed.aaf6953.
33. Irani JN, Ronse M, Rujumba J, Njamnshi A, Mwaka A, Idro R, et al. The
gendered burden of nodding syndrome in Cameroon, Tanzania and
Uganda. In: 1st International Workshop on Onchocerciasis-Associated
Epilepsy. 12-14 October 2017 Antwerp, Belgium [Abstract 19]. Available:
https://www.uantwerpen.be/images/uantwerpen/container42952/files/
20171023%20Programma%20boekje%20FINAL.pdf. Accessed 21 Dec 2017.
Colebunders et al. Infectious Diseases of Poverty  (2018) 7:23 Page 5 of 5
